Centene is a large managed care company that manages healthcare programs for nearly 28 million people, primarily through government-sponsored plans like Medicaid. It generated $163.07 billion in revenue in 2024, acting as a critical bridge between state governments and low-income or elderly populations. While the business has faced recent turbulence from redeterminations—the process where states re-verify Medicaid eligibility—it remains a dominant force in the health insurance marketplace where it grew membership by 12% last year.
The investment thesis on Centene is that it is a essential government partner trading at a steep discount because the market overestimates the permanent damage from Medicaid membership losses. Centene has spent the last two years simplifying its business, selling off non-core units to focus on its high-growth Marketplace and Medicaid segments. As the Medicaid population stabilizes and the company continues to aggressively buy back its own shares, earnings per share should grow even if total membership stays flat.
We think Centene is an exceptionally rare opportunity to buy a essential utility-like business at a price that suggests its best days are over, when the data shows its core segments are actually getting more efficient. The company has already provided a 2025 earnings floor that is higher than its 2024 performance, proving its ability to manage through policy shifts. The primary risk is a significant change in federal healthcare law, but Centene’s role in managing state budgets makes it a very difficult partner for any administration to replace.
Centene’s stock stayed mostly flat for years but has soared lately. The company lost many members when government programs rechecked who qualified for health coverage, which forced them to cut costs and offer buyouts to staff. Investors now realize that the business remains an essential partner for states, helping the price climb back up.
What does it do?
Centene is a mature managed care organization that earns money by receiving fixed monthly payments from state and federal governments to manage the healthcare of their members. The company acts as an intermediary: it collects premiums from the government and then pays doctors and hospitals for the care its members receive. Centene keeps the difference between the premiums collected and the claims paid out, a margin known as the underwriting profit. Because these payments are fixed, Centene makes more money when it helps members stay healthy and avoids unnecessary, high-cost hospital visits.
Where does revenue come from?
The vast majority of revenue comes from government contracts, specifically through the Medicaid and Medicare programs. Medicaid, which serves low-income individuals, is the largest piece of the business, followed by the Commercial segment which includes the Health Insurance Marketplace. Medicare serves seniors through Advantage and Part D prescription plans. Centene is entirely focused on the United States, with its revenue tied to state-level contracts across nearly all 50 states.
Revenue Breakdown
Who are its customers?
Centene serves roughly 28 million total members, including over 13 million in Medicaid and 4 million in the commercial Marketplace. Its primary "customers" are actually state governments that outsource their healthcare programs to Centene to save money and improve care quality. In 2024, Marketplace membership grew by 12% and Medicare prescription drug (PDP) membership surged by 50%. The company provides services to one in 15 Americans, giving it massive scale that helps it negotiate better prices with hospitals and pharmacies.
What gives it staying power?
Centene's staying power comes from its massive scale and the extreme complexity of managing state healthcare regulations. Once a state signs a multi-year contract with Centene, switching to a new provider is a massive administrative headache that risks disrupting care for millions of vulnerable people. This creates high switching costs at the government level.
Where is it headed?
Centene is moving toward a "leaner" business model by selling off international units and pharmacy businesses to focus purely on its core U.S. insurance plans. Management is betting that by simplifying the company, they can improve profit margins and use the extra cash to buy back shares. This shift is intended to transform Centene from a complex conglomerate into a high-efficiency health insurer.
Verdicts on Revenue & Earnings Trend: Centene is successfully growing its core revenue base despite the headwind of losing millions of Medicaid members. Revenue reached $163.07 billion in 2024, up from $154 billion the year prior, as growth in the Commercial Marketplace offset Medicaid losses. While the company reported a large GAAP loss in late 2024 due to non-cash restructuring costs, its adjusted earnings per share actually rose 7% to $7.17.
Verdict on Cash Generation: Free cash flow is lumpy due to the timing of government payments but remains fundamentally strong. The company generated $4.32 billion in free cash flow in its most recent fiscal year, which it used to fund $3.0 billion in share repurchases. This ability to return cash to shareholders while navigating a difficult regulatory period proves the underlying health of the insurance engine.
Verdict on the Balance Sheet: Centene maintains a resilient balance sheet with a debt-to-equity ratio of 0.76x. This level of leverage is conservative for a business with such predictable government-backed revenue streams. The company holds significant cash and investment reserves to cover its future medical claims, ensuring it can meet its obligations even if healthcare costs spike unexpectedly.
Centene is a financially massive cash machine that is currently using its scale to buy back a significant portion of its own undervalued stock.
The Marketplace segment is acting as a powerful growth engine, with membership increasing 12% in the last year. This is critical because it proves Centene can keep its customers even when they lose Medicaid eligibility by moving them into its commercial plans. This "bridge" keeps the revenue inside the company and protects its total membership base.
The Health Benefit Ratio (HBR) is the single most important number to track, as it is expected to stay near 87.9%. If medical costs rise faster than the premiums Centene receives from states, this ratio will climb and eat into profit margins. Any spike in hospital usage or pharmacy costs could quickly derail the company's 2025 earnings targets.
The U.S. managed care industry is a multi-trillion dollar market that grows steadily as healthcare costs rise and the population ages. It is a mature industry where pricing power is limited by government regulation, making scale the single most important factor for survival and profit. Centene stands as one of the few players with enough volume to manage the massive administrative burden of state contracts. This scale provides a significant growth runway as more states outsource their complex healthcare programs to private insurers.
The competitive dynamic in government-sponsored healthcare is rationally structured but intensely focused on scale and operational efficiency. Winning or losing a single large state contract can move billions in revenue overnight. Barriers to entry are incredibly high because a new player would need thousands of doctor contracts and a massive regulatory team just to submit a bid.
UnitedHealth and Elevance are the primary threats because they have larger balance sheets and can sometimes underbid Centene to win territory. UnitedHealth in particular uses its Optum pharmacy unit to lower its own costs, a tool Centene no longer has. The most dangerous threat is a competitor winning a multi-year contract in a major state like California or Florida.
Centene is currently holding its ground in a consolidating market. While it has lost some Medicaid members due to eligibility checks, its 12% growth in Marketplace members proves it is winning share in the commercial space. Centene remains a top-three player in its core markets.
Centene’s primary protection is efficient scale and the regulatory moat that comes from being a essential state partner. The company manages healthcare for nearly 28 million people, creating a level of local density that makes it nearly impossible for a small insurer to compete. This scale allows Centene to spread its massive compliance and technology costs over a huge number of members.
The 14.9% gross margin and low net margins are typical for the industry and reflect a business that operates on thin slices of massive revenue. The ROIC is currently distorted by non-cash impairments, but the $4.32 billion in free cash flow proves the business model is durable. Centene's moat is real but narrow because it depends entirely on maintaining good relationships with state governments.
The forward-looking verdict is that this moat is stable. The single most important signal is Centene’s ability to win contract renewals, which it continues to do at a high rate. As long as Centene remains a essential budget-saving tool for states, its market position is secure.
Delivered $7.17 adjusted EPS in 2024, beating the initial guidance floor.
Repurchased $3.0 billion of stock in 2024 while the shares were undervalued.
Insiders own roughly 0.2% of the company, valued at over $60 million.
Capital Allocation Track Record
Sarah London has done a remarkable job of simplifying what was once a messy and overly complex conglomerate. Since taking the helm, she has moved away from distracting international expansions and pharmacy businesses to focus entirely on Centene's core strength: managing government-sponsored healthcare plans. This strategic pivot has improved the company's focus and allowed it to deliver adjusted earnings growth even during a difficult period for the industry. Her decision to use billions in cash to buy back shares at a low price shows a sophisticated understanding of shareholder value.
The primary risk to management is the company's heavy dependence on her personal vision for this "simpler" Centene. While she has a strong bench of experienced executives, the multi-year transformation she started is still in its middle stages. There is no major key-person risk, but a leadership change now could lead to a reversal of the current disciplined capital allocation strategy. The board remains independent and has supported her focus on core operations, which reduces the risk of the company returning to its old, fragmented ways.
We expect revenue to grow from $191B in FY2026 to $226B in FY2031 (~3% CAGR), with EPS growing from $3.48 to $10.98 (~26% CAGR). Revenue growth is driven by the steady expansion of government-sponsored healthcare programs and the recovery of Medicaid membership levels following the redetermination period. Operating margins improve as the company moves past one-time restructuring costs and optimizes its premium- Operating margin expected to reach ~4% by FY2031.
Marketplace membership expansion replaces declining Medicaid enrollment. As millions of people lose Medicaid eligibility, Centene is successfully moving them into its own Marketplace plans which carry higher margins.
Margin expansion through Value-Based Care and technology. Implementing more efficient healthcare management tools will lower the company's HBR and drop more revenue to the bottom line.
Massive share count reduction through continued buybacks. If Centene continues to buy back 5% to 8% of its shares annually, EPS will grow significantly even with modest revenue growth.
Political shifts and changes to the Affordable Care Act. A change in federal administration or a Supreme Court ruling could alter the subsidies that make the Marketplace business profitable.
States cutting Medicaid reimbursement rates to balance budgets. If states face their own budget crises, they may lower the premiums they pay Centene, squeezing profit margins.
Higher than expected medical usage among remaining members. If the healthiest people leave Medicaid and the sickest stay, the cost to manage the remaining population will spike.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach (price-to-earnings applied to next year's earnings) to derive the fair value. It fits Centene because the company is a mature insurer where earnings power is the primary driver of value, and focusing on FY2027 captures the first "clean" year of profitability after the restructuring and volatility seen in 2025. This framework allows us to value the business based on its normalized earnings capacity rather than its recent GAAP losses.
Multiplying our FY2027 EPS estimate of $4.50 by a 15x multiple gives a per-share fair value of $68. A 15x multiple sits at the higher end of Centene's historical 10-14x range but remains well below sector leaders UnitedHealth (19x) and Elevance (17x). This premium over historical levels is justified by the increasing mix of high-margin Commercial revenue, which now accounts for 21.6% of the business. The $4.50 EPS input is sourced directly from the deterministic projection for FY2027.
A 5-year Discounted Cash Flow (DCF) cross-check yields a fair value of $115, suggesting our Forward P/E approach is significantly conservative. While the DCF captures the long-term value of Centene's massive $195B+ revenue base scaling toward $213B by 2030, we consider the $115 figure to be "aspirational" as it requires high-single-digit margin expansion that has not yet been proven. The 69% disagreement between the two methods is evidence that the market is still pricing in high regulatory risk for government-sponsored plans. We trust the $68 P/E-based target as a more realistic near-term anchor for retail investors.
We're assuming the Health Benefits Ratio (HBR) — the percentage of premiums spent on medical care — normalizes to approximately 87.5% by FY2027. This matches the Q1 2026 result of 87.3% and reflects management's efforts to re-price plans following a challenging 2025. Given that utilization spiked during the post-pandemic redetermination process, a stabilization at these levels is a reasonable mid-cycle expectation.
We're assuming membership in the high-margin Commercial Marketplace segment grows at a 5% annual rate through 2028. While growth was much higher in 2025 (29.5%), a deceleration is expected as the pool of individuals transitioning from Medicaid to private plans stabilizes. This segment is the primary engine for profit growth, as these plans typically generate better margins than government-sponsored Medicaid.
The biggest risk is that Medicaid medical utilization costs persistently outpace the rates states are willing to pay. This would prevent the margin recovery expected in 2026, compressing the forward multiple from 15x to 12x and knocking roughly $14 off the per-share fair value. Watch the "Health Benefits Ratio" (HBR) in quarterly reports; any print above 89% suggests the re-pricing strategy is falling behind.
Bear case ($55): Medicaid Health Benefits Ratio (HBR) remains above 91% for two consecutive quarters, signaling failed re-pricing; or Congressional action significantly reduces the subsidies for the ACA Marketplace segment, leading to a 15% membership drop.
Bull case ($85): Commercial Marketplace membership growth exceeds 30% while maintaining an HBR below 85%; or Centene achieves a 4-star Medicare Advantage rating for its major plans, unlocking material bonus payments.
Clearthesis wrote this report from 38 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning bullish because Centene is cutting internal costs and stabilizing its massive government insurance business after recent losses. Management is actively trimming its workforce through buyouts to right-size expenses while maintaining its role as a primary provider for government programs that serve nearly 28 million people.
Skeptics think that Centene will struggle to grow because state governments are still actively removing people from Medicaid rolls. Ongoing member losses from strict state eligibility reviews could permanently shrink the company's customer base faster than their current cost-cutting efforts can protect future profit margins.